leisure time -WSS

leisure time

author：comprehensive 2025-09-06 04:38:12 - browse：22767

This image provided by Eisai in January 2023 shows vials and packaging for their medication, Leqembi. — A newly approved Alzheimer’s drug made by Eisai and Biogen, called Leqembi, aims to clear out amyloid plaques in patients’ brains. Illustration: Alex Hogan/STAT; Photo: Eisai via AP

WASHINGTON — Medicare on Monday proposed ending restrictions on how many PET scans patients can receive to detect amyloid plaques in their brains, which will offer physicians more options as they treat patients with a new drug to slow the progression of dementia.

The agency that oversees Medicare had previously restricted coverage to a single scan for patients who participated in clinical studies. Advocates had warned that could cause issues related to a new class of Alzheimer’s drugs designed to clear those plaques.

“We know there is significant interest in the medical community about new treatments that may be effective in slowing the development of Alzheimer’s disease. PET scans are an important part of diagnosis and treatment of Alzheimer’s disease,” Centers for Medicare and Medicaid Administrator Chiquita Brooks-LaSure said in a written statement.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Medicare proposal to cover medical devices draws a mixed reaction
Next article： Can CDC director Mandy Cohen drive consensus in Washington?

WSS

How to convince healthy people to buy insurance

Live blog: Hearing on CRISPR

Involuntary treatment for addiction doesn't work

Explaining an after

4 killed in mass shooting in Georgia, shooter remains on the loose: Police

The new HIV moral panic

leisure time

leisure time

focus

DIEP, the 'gold standard' of breast reconstruction, is under threat

All of Us, NIH's precision medicine initiative, gets a big boost

Hepatitis C has a cure — but many Americans still lack access to it

After Sarepta trial failure, Duchenne families brace for more debate

The high cost of giving birth even with insurance

Explaining an after

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Congress: Eradicate hepatitis C and reduce the deficit

Alkermes shareholders re

Inari Medical to buy amputation prevention company LimFlow

Wikipedia

Live blog: Hearing on CRISPR

What is microchimerism and how does it affect maternal health?

Infant mortality in U.S. rose last year for first time in decades: CDC

Does aspartame cause cancer? What new WHO guidance says

Humans aren't the only ones with an imagination. Rats have it too

The health care issue Democrats can’t solve: hospital reform

hotspot

explore

focus

focus